Leonteq Securities AG’s BridgeBio Pharma BBIO Stock Holding History

Leonteq Securities AG’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	4,013 +1,989	+98%	+$139K	0.01%	497
2026 Q1	$150K	Sell	2,024 -570	-22%	-$41.3K	0.01%	649
2025 Q4	$198K	Sell	2,594 -1,500	-37%	-$98.5K	0.01%	670
2025 Q3	$213K	Buy	4,094 +3,810	+1,342%	+$186K	0.01%	596
2025 Q2	$12.3K	Sell	284 -370	-57%	-$13.5K	﹤0.01%	1038
2025 Q1	$22.8K	Sell	654 -3,778	-85%	-$127K	﹤0.01%	965
2024 Q4	$122K	Sell	4,432 -1,086	-20%	-$28.1K	0.01%	645
2024 Q3	$140K	Sell	5,518 -2,551	-32%	-$67K	0.01%	557
2024 Q2	$204K	Buy	8,069 +1,443	+22%	+$39.5K	0.01%	483
2024 Q1	$205K	Buy	+6,626	New	+$225K	0.02%	494

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Leonteq Securities AG's BBIO Position: Q2 2026 in Review

Leonteq Securities AG increased its BridgeBio Pharma (BBIO) stake by 98% in Q2 2026, buying an estimated $139K and bringing the position to 4,013 shares worth $299K. The position accounts for 0.01% of the portfolio, ranked #497.

Leonteq Securities AG first reported a position in BBIO in Q1 2024 and has held it in 10 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Leonteq Securities AG held 4,013 shares of BridgeBio Pharma worth $299K as of Q2 2026.
Leonteq Securities AG bought 1,989 BridgeBio Pharma shares in Q2 2026, an estimated $139K.
BridgeBio Pharma made up 0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #497 holding.
Leonteq Securities AG first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 10 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.